Are KIR-HLA polymorphisms relevant for the outcome of chronic inf
Immunogenetics: Open Access

Immunogenetics: Open Access
Open Access

+44 1223 790975

Review Article - (2018) Volume 3, Issue 1

Are KIR-HLA polymorphisms relevant for the outcome of chronic infected hepatitis C virus patients?

Larisa Denisa Ursu1,2, Carmen Monica Preda1,3, Mircea Diculescu1,2 and Ileana Constantinescu1,2*
1Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
2Centre for Immunogenetics and Virology, Fundeni Clinical Institute, Bucharest, Romania
3Department of Gastroenterology & Hepatology, Fundeni Clinical Institute, Bucharest, Romania
*Corresponding Author: Ileana Constantinescu, Centre for Immunogenetics and Virology, Fundeni Clinical Institute, Bucharest, Romania, Tel: +40213180448 Email:


Natural killer (NK) cells play an important role in viral clearance and in the elimination of neoplastic cells. Recent cellular and genetic studies revealed that NK cells modulate the immune response against hepatitis C virus (HCV). Improving our understanding of NK cells could help us gain further insight into the virus-host interaction and the mechanisms of viral persistence. Previous studies mention the role of Killer cell Immunoglobulin-like Receptors (KIRs) and their Human Leukocyte Alleles (HLA) ligands in disease progression of chronic HCV infected patients. Specific HLA class I and class II alleles may influence the susceptibility or resistance to persistent HCV infection. In the last few years, progress has been made in the link between KIR-HLA gene polymorphisms and susceptibility to immune-mediated diseases such as chronic HCV infection. Many studies have shown the importance of NK cells in the outcome of chronic HCV patients. The immune response against HCV is affected by certain KIR genes and HLA genes. There is a great potential for the use of KIR genes as a prognostic tool for the development of complications such as liver cirrhosis and HCC.

Keywords: Chronic HCV; NK cells; KIR genes; HLA alleles; Spontaneous clearance; Viral replication; Viral persistence


HCV-Hepatitis C Virus; NK-Natural Killer; KIR-Killer-cells Immunoglobulin-like Receptors; HLA-Human Leukocyte Antigens; MHC-Major Histocompatibility Complex; HCC-Hepatocellular Carcinoma; SVR-Sustained Virological Response; Peg- IFN-Pegylate Alpha Interferon; IFNL3-Interferon Lambda-3


HCV is a major public health problem worldwide with an estimated population of 71 million people suffering from chronic hepatitis C infection. Approximately 3,99,000 people die each year from hepatitis C, mostly from complications like cirrhosis and hepatocellular carcinoma (HCC) [1]. HCV prevalence varies around the world. Regarding HCV genotypes in Europe, the most common subtype is 1b whilst in America the most frequent subtype is 1a. In the Middle East, North and Central Africa, the most prevalent genotype is 4 and in Asia, it is genotype is 3 [2,3]. HCV infection has two possible outcomes: spontaneous clearance or chronic infection [4]. Memory T helper cells and/or cytotoxic T lymphocytes can provide protection against HCV and contribute to spontaneous clearance [5]. A significant number of chronic HCV-infected patients could develop complications such as cirrhosis and hepatocellular carcinoma (HCC) in the late stages [6].

Natural killer cells are a type of lymphocyte involved in the innate anti-viral immune response. They were first mentioned in the 1970s. NK cells have a crucial role in the prevention and progression of cancer and in immune surveillance as well [7-11]. The function of the NK cell is controlled by killer-cell immunoglobulin-like receptors (KIR), a family of type I transmembrane glycoproteins which recognize HLA class I molecules [12,13]. According to the “missing self ” hypothesis, one important function of NK cells is to detect and eliminate cells if they fail to express normal self-antigens. [14]. A strategy to discriminate between normal and infected cells is the interaction with major histocompatibility complex (MHC) class I proteins [15]. MHC class I molecules are expressed on the surface of all nucleated cells. Both virus-infected cells and neoplastic cells have a decreased expression of MHC-class I and therefore are targets for NK cells [16].

Human KIR haplotypes are encoded by chromosome 19q13.4. They are divided into two groups: group ‘A’ and group ‘B’. The ‘A’ haplotype consists mostly of KIR genes for inhibitory receptors and the ‘B’ haplotype contains genes for both activating and inhibitory receptors [17,18]. If none of the following KIR genes: KIR2DL2 , KIR2DL5 , KIR3DS1 , KIR2DS1 , KIR2DS2 , KIR2DS3 , KIR2DS5 are present, the genotype is AA. If any of these genes are present, the haplotype is B. When we can’t distinguish between AB and BB genotypes, the genotype is known as Bx [19]. The interaction between KIR and HLAC molecules is the dominant control mechanism of human NK cells. A minority of HLA-A and HLA-B alleles function as KIR ligands [20]. Scientists are particularly interested in certain combinations of activating or inhibitory KIR and their HLA ligands could have implications in the clinical outcome of chronic HCV infection.

Association Of Chronic HCV Infection Outcome With KIR-HLA Class I Genes

Many studies have shown the influence of KIR-HLA combinations in the outcome of chronic HCV infection. Certain HLA class I molecules are associated with HCV spontaneous clearance. KIR2DL1 receptors recognize HLA-C group 2 antigens (that present amino acid lysine in position 80), KIR2DL2 /3 receptors recognize HLA-C group 1 antigens (that present amino acid asparagine in position 80) and KIR3DL1 is the receptor for HLA Bw4 molecules [21-23]. In regards to inhibitory genes, a link between KIR2DL2 and chronic persistent HCV infection was observed [24,25]. The affinity of the KIR2DL2 to the HLA-C ligand is higher than that of KIR2DL3 , which has a stronger inhibition of the NK cell [13,25,26].

NK cells contribute to the resolution of HCV infection through KIR2DL3/HLA-C1 interaction. Several studies have revealed the combination of group 1 HLA-C genes with KIR2DL3 homozygosity has been associated with HCV clearance [26,27] and has also been associated with a sustained viral response to antiviral therapy [28,29]. A better outcome was observed in individuals with this combination of receptor and ligand (KIR2DL3/HLA-C1). One possible explanation might be exposure to virus. The beneficial effect of KIR2DL3/HLAC1/ C1 was only seen in the non-transfusion group, suggesting that NK cells may be an important part of the immune response when there is a limited exposure to virus [26,27].

Studies that compare patients who spontaneously resolved infection and patients who developed chronic HCV have been revealed that KIR2DS3 gene is significantly more prevalent in patients with chronic HCV infection [30-32]. The association of KIR2DS3 with chronic infection was influenced by the HLA-C genetic background. KIR2DS3 was only significantly increased in patients with chronic HCV infection and a HLA-C2+ genetic background [30,31]. This suggests that certain KIR-haplotypes were more common in patients with chronic HCV infection. Vasconcelos et al. also described in the Brazilian population an association of KIR2DS3 (either alone or together with KIR2DL2 and KIR2DS2 ) with chronic HCV infection [28]. Related to KIR genes involved in susceptibility to chronic HCV infection and to viral load levels, the data has shown a difference between viremia levels in KIR2DS3 +/KIR2DS5- patients versus other combinations of these two genes. Patients with KIR2DS3 but not KIR2DS5 gene have lower levels of viremia [33]. However, in a recent study, conducted by Podhorzer et al. KIR2DS3 expression was correlated with high viral load levels [34]. The contribution of this gene to chronic HCV infection requires further studies in ethnically different populations.

In a study looking at the risk of developing HCC and lymphoproliferative disease progression in Italian patients with chronic HCV infection showed KIR2DS5 gene has a protective effect against disease progression when associated with KIR2DS3 gene. These results suggest that low expression of activating KIR genes 2DS3 and 2DS5 leads to a reduction in the activation of NK cells in lymphoproliferative disorders. An increased risk of HCC was associated with a reduction of HLA-Bw4+KIR3DS1+ in the same cohort study [20].

Another study in Japan looking at the risk of hepatitis C virusrelated HCC in young patients showed associations between KIR2DL2-HLA-C1 and KIR2DS2-HLA-C1 were significantly higher in younger patients who developed HCC. This study also revealed that patients with chronic hepatitis C had a significantly higher incidence rate of KIR3DL1-HLA-Bw4 pairs [35].

The following HLA alleles configuration HLA-A*03, B*27, DRB1*01:01, DRB1*04:01 are strongly associated with HCV viral clearance while DQB1*02:01 is associated with chronic infection [28].

Correlations Between KIR - HLA Class II Alleles And Chronic HCV Infection Outcome

Particularly DRB1 and DQB1 alleles are associated with spontaneous resolution of HCV infection. Some associations were tested in the Caucasians, Asians and Hispanic populations. KIR-HLA polymorphisms also influence the susceptibility to chronic HCV and response to antiviral therapy. The importance of interferon lambda and innate immunity in the outcome of HCV infection was also described by Frias et al. Interferon lambda-3 (IFNL3) genotype was found in patients with self-limiting acute HCV infection [36].

A rapid reduction in viremia by direct acting antiviral therapy improves the response to PegIFN in patients who had previously failed to respond to standard PegIFN/ribavirin (RBV) therapy [37].

In Caucasians, HLA-DRB1*16:01 was associated with higher rates of spontaneous clearance, while DRB4*01:01, HLA-DRB1*07 and DRB1*07:01 were associated with lower rates of spontaneous HCV clearance [35]. HLA-DRB1*0701 was also reported as being correlated with a lack of response to antiviral therapy and higher viral loads [38].

Other studies investigated whether HLA class II alleles influenced the clinical outcome of HCV infection and response to interferon therapy in the Egyptian population. It was revealed that the DQB1*02, DQB1*06, DRB1*13, DRB1*15, DRB1*13:01, DRB1*13:61 and DRB1*13:69, may act as positive predictors for response to interferon treatment. These alleles were more frequently present in responders than in non-responders [29].


Many studies have shown that NK cells are linked to their KIR genotypes and they have a protective role against the HCV viral loads. Different interactions between KIR and HLA class I and class II molecules have an influence on the immunopathogenesis of chronic HCV and have a significant impact on NK cell function. These HLA molecules in association with KIR genes may be used as predictors for response to interferon treatment or for the outcome of chronic HCV infection. KIR-HLA polymorphisms are clinically relevant for the course of chronic HCV infection, affecting patient’s clinical status and potential development of a liver tumor. HCV recurrence is lower among patients with a larger number of activating KIR genes. The immune response against HCV is complex. Interactions between NK cells-KIR genes and HLA genes are challenging and could offer more answers for the different outcomes of HCV infected patients. Further research is required to shed some light on HCV immunopathogenesis.


  1. References Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology. 2005;42(4):962-73. PMid:16149085 Rosen HR. Clinical practice. Chronic hepatitis C infection. N Engl J Med. 2011;364(25):2429-38. PMid:21696309 Noorali S, Pace DG, Bagasra O. Of lives and livers: emerging responses to the hepatitis C virus. J Infect Dev Ctries. 2011;5(1):1-17. PMid:21330735 Morice Y, Cantaloube JF, Beaucourt S, Barbotte L, De Gendt S, Goncales FL, et al. Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users. J Med Virol. 2006;78(10):1296-303. PMid:16927280 Gervain J, Simon Jr G, Simon J; Hungarian Viral Hepatitis Group. Genotype distribution of hepatitis C virus in the Hungarian population with chronic viral hepatitis C Eur J Gastroenterol Hepatol. 2003;15(4):449-50. PMid:12655271 Müller Z, Deák J, Ross RS, Nagy E, Kovács L, Roggendorf M, et al. Hepatitis C virus genotypes in Hungarian and Austrian patients with chronic hepatitis C. J Clin Virol. 2003;26(3):295-300. European Centre for Disease Prevention and Control (ECDC). Annual Epidemiological Report 2011. Reporting on 2009 surveillance data and 2010 epidemic intelligence data. Stockholm: ECDC; 2011. Available from: Bozsonyi K, Csesztregi T, Dudás M, Horváth GC, Keller É, Koós T, et al. 2010 National Report to the EMCDDA by the Reitox National Focal Point. Hungary. New developments, trends and in-depth information on selected issues. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). [Accessed 3 Dec 2012]. Available from: Csesztregi T, Dudás M, Felvinczi K, Horváth GC, Huszár L, Koós T, et al. 2011 National Report to the EMCDDA by the Reitox National Focal Point. Hungary. New developments, trends and in-depth information on selected issues. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). [Accessed 3 Dec 2012]. Available from: Bánhegyi D, Böröcz K, Kertész A, Melles M, Milassin M, Pechó Z, et al. Tájékoztató a betegellátás során a vérrel és testváladékokkal terjedő vírusfertőzések megelőzéséről. Epinfo. 2003;10(2. különszám):1-39. Tresó B, Barcsay E, Tarján A, Horváth G, Dencs A, Hettmann A, et al. Prevalence and Correlates of HCV, HVB, and HIV Infection among Prison Inmates and Staff, Hungary. J Urban Health. 2012;89(1):108-16. PMid:22143408 PMCid:PMC3284587 Dencs A, Hettmann A, Martyin T, Jekkel C, Bányai T, Takács M. Phylogenetic investigation of nosocomial transmission of hepatitis C virus in an oncology ward. J Med Virol. 2011;83(3):428-36. PMid:21264863 Cochrane A, Searle B, Hardie A, Robertson R, Delahooke T, Cameron S, et al. A genetic analysis of hepatitis C virus transmission between injection drug users. J Infect Dis. 2002;186(9):1212-21. PMid:12402190 Hickman M, McDonald T, Judd A, Nichols T, Hope V, Skidmore S, et al. Increasing the uptake of hepatitis C virus testing among injecting drug users in specialist drug treatment and prison settings by using dried blood spots for diagnostic testing: a cluster randomized controlled trial. J Viral Hepat. 2008;15(4):250-4. PMid:18086182 Abe K, Konomi N. Hepatitis C virus RNA in dried serum spotted onto filter paper is stable at room temperature. J Clin Microbiol. 1998 Oct;36(10):3070-2. PMid:9738072 PMCid:PMC105116 Hope VD, Hickman M, Ngui SL, Jones S, Telfer M, Bizzarri M, et al. Measuring the incidence, prevalence and genetic relatedness of hepatitis C infections among a community recruited sample of injecting drug users, using dried blood spots. J Viral Hepat. 2011;18(4):262-70. PMid:20456636 Mahfoud Z, Kassak K, Kreidieh K, Shamra S, Ramia S. Distribution of hepatitis C virus genotypes among injecting drug users in Lebanon. Virol J. 2010;7:96. PMid:20465784 PMCid:PMC2885342 Tuaillon E, Mondain AM, Meroueh F, Ottomani L, Picot MC, Nagot N, et al. Dried blood spot for hepatitis C virus serology and molecular testing. Hepatology. 2010;51(3):752-8. PMid:20043287 Pybus OG, Cochrane A, Holmes EC, Simmonds P. The hepatitis C virus epidemic among injecting drug users. Infect Genet Evol. 2005;5(2):131-9. PMid:15639745 Seme K, Poljak M, Lesnicar G, Brinovec V, Stepec S, Koren S. Distribution of hepatitis C virus genotypes in Slovenia. Scand J Infect Dis. 1997;29(1):29-31. PMid:9112294 Vince A, Iscić-Bes J, Zidovec Lepej S, Baća-Vrakela I, Bradarić N, Kurelac I, et al. Distribution of hepatitis C virus genotypes in Croatia--a 10 year retrospective study of four geographic regions. Coll Antropol. 2006;30 Suppl 2:139-43. PMid:17508487 Krekulová L, Rehák V, Strunecký O, Nēmecek V. [Current situation and trends in the hepatitis C virus genotype distribution among injecting drug users in the Czech Republic]. Epidemiol Mikrobiol Imunol. 2009;58(2):84-9. Czech. PMid:19526922 Chlabicz S, Flisiak R, Lapinski TW, Kowalczuk O, Wiercinska-Drapalo A, Pytel-Krolczuk B, et al. Epidemiological features of patients infected with HCV genotype 4 in Poland: Epidemiology of HCV genotype 4 in Poland. Hepat Mon. 2011;11(3):191-4. PMid:22087142 PMCid:PMC3206688 HCV sequence database. [Accessed 28 Feb 2012]. Available from: Infektológiai Szakmai Kollégium. [Infectious Diseases Advisory Board]. A Nemzeti Erőforrás Minisztérium szakmai protokollja a C hepatitis antivirális kezeléséről. [The Ministry of National Resources' professional protocol for hepatitis C antiviral treatment]. Egészségügyi Közlöny. [Official Bulletin of the Ministry of National Resources in Hungary]. 2011;61(7):1393-401. Kronenberger B, Zeuzem S. New developments in HCV therapy. J Viral Hepat. 2012;19 Suppl 1:48-51. PMid:22233414
  2. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61: S45-S57.
  3. Lauer GM, Walker BD (2001) Hepatitis C virus infection. N Engl J Med 345: 41-52.
  4. Park SH, Shin EC, Capone S, Caggiari L, De Re V, et al. (2012) Successful vaccination induces multifunctional memory t-cell precursors associated with early control of hepatitis C virus. Gastroenterology 143: 1048-1060.
  5. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, et al. (2003) Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 197: 1645-1655
  6. Rosenberg EB, Herberman RB, Levine PH, Halterman RH, McCoy JL, et al. (1972) Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer 9: 648-658.
  7. Herberman RB, Nunn ME, Holden HT, Lavrin DH (1975) Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16: 230-239.
  8. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
  9. Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, et al. (2013) A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet 45: 164-171.
  10. Gardiner CM (2015) NK cell function and receptor diversity in the context of HCV infection. Front Microbiol 6: 106.
  11. Moretta L, Moretta A (2004) Killer immunoglobulin-like receptors. Curr Opin Immunol 16: 626-633.
  12. Parham P (2005) MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 5: 201-214.
  13. Shifrin N, Raulet DH, Ardolino M (2014) NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol 26: 138-144.
  14. Karre K (2002) NK cells, MHC class I molecules and the missing self. Scand J Immunol 55: 221-228.
  15. Ljunggren HG, K¨arre K (1990) In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today 11: 237-244.
  16. Jiang W, Johnson C, Jayaraman J, Simecek N, Noble J, et al. (2012) Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. Genome Res 22: 1845-1854.
  17. Parham P, Norman PJ, Abi-Rached L, Guethlein LA (2012) Human-specific evolution of killer cell immunoglobulin-like receptor recognition of major histocompatibility complex class I molecules. Philos Trans R Soc Lond B Biol Sci 367: 800-811.
  18. Norman PJ, Hollenbach JA, Nemat-Gorgani N, Guethlein LA, Hilton HG, et al. (2013) Co-evolution of human leukocyte antigen (HLA) class I ligands with killer-cell immunoglobulin-like receptors (KIR) in a genetically diverse population of sub-Saharan Africans. PLoS Genet 9: e1003938.
  19. Boyington JC, Sun PD (2002) A structural perspective on MHC class I recognition by killer cell immunoglobulin-like receptors. Mol Immunol 38: 1007-1021.
  20. Winter CC, Long EO (1997) A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol 158: 4026-4028.
  21. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, et al. (2011) Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
  22. Guethlein LA, Norman PJ, Hilton HG, Parham P (2015) Co-evolution of MHC class I and variable NK cell receptors in placental mammals. Immunol Rev 267: 259-282.
  23. Vidal-Castiñeira JR, López-Vázquez A, Díaz-Peña R, Alonso-Arias R, Martínez-Borra J, et al. (2010) Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. J Virol 84: 475-481.
  24. Vejbaesya S, Nonnoi Y, Tanwandee T, Srinak D (2011) Killer cell immunoglobulin-like receptors and response to antiviral treatment in Thai patients with chronic hepatitis C virus genotype 3a. J Med Virol 83: 1733-1737.
  25. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, et al. (2004) HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection. Science 305: 872-874.
  26. Knapp S, Warshow U, Hegazy D, Brackenbury L, Guha IN, et al. (2010) Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. Hepatology 51: 1168-1175.
  27. Janaina Mota de Vasconcelos (2013) Association of killer cell immunoglobulin-like receptor polymorphisms with chronic hepatitis C and responses to therapy in Brazil. Genet Mol Biol 36: 22-27.
  28. Shaker O, Bassiony H, El Raziky M, El-Kamary SS, Esmat G, et al. (2013) Human Leukocyte Antigen Class II Alleles (DQB1 and DRB1) as Predictors for Response to Interferon Therapy in HCV Genotype 4. Mediators Inflamm 2013: 392746.
  29. Dring MM, Morrison MH, McSharry BP, Guinan KJ, Haga R, et al. (2011) Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci USA 108: 5736-5741.
  30. Fitzmaurice K, Hurst J, Dring M, Rauch A, McLaren PJ, et al. (2015) Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. Gut 64: 813-819.
  31. Gauthiez E, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, et al. (2017) A systematic review and meta-analysis of HCV clearance. Liver Int 1431-1445.
  32. Kusnierczyk P, Mozer-Lisewska I, Zwolinska K, Kowala-Piaskowska AE, Bura M, et al. (2015) Contribution of genes for killer cell immunoglobulin-like receptors (KIR) to the susceptibility to chronic hepatitis C virus infection and to viremia. Hum Immunol 76: 102-108.
  33. uthiez E, Habfast-Robertson I, Rüeger S, Kutalik Z, Aubert V, et al. (2017) A systematic review and meta-analysis of HCV clearance. Liver Int 1431-1445.
  34. Saito H, Umemura T, Joshita S, Yamazaki T, Fujimori N, et al. (2018) KIR2DL2 combined with HLA-C1 confers risk of hepatitis C virus-related hepatocellular carcinoma in younger patients. Orcotarget 9: 19650-19661.
  35. Podhorzer A, Dirchwolf M, Machicote A, Belen S, Montal S, et al. (2017) The Clinical Features of Patients with Chronic Hepatitis C Virus Infections Are Associated with Killer Cell Immunoglobulin-Like Receptor Genes and Their Expression on the Surface of Natural Killer Cells. Front Immunol 8: 1912.
  36. Frias M, Rivero-Juárez A, Rodriguez-Cano D, Camacho Á, López-López P, et al. (2018) HLA-B, HLA-C and KIR improve the predictive value of IFNL3 for Hepatitis C spontaneous clearance. Sci Rep 8: 659.
  37. De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, et al. (2015) Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. PLoS One 10: e0117420.
Citation: Ursu LD, Preda CM, Diculescu M, Constantinescu I (2018) Are KIR-HLA Polymorphisms Relevant for the Outcome of Chronic Infected Hepatitis C Virus Patients? Immunogenet Open Access 3: 122.

Copyright: © 2018 Ursu LD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.